Nabsys

Today is Fragile X Awareness Day 🧬 Fragile X syndrome, caused by caused by a triplet repeat expansion in the FMR1 gene, is the most common inherited cause of intellectual disability and a leading known single-gene cause of autism. Increasing awareness helps advance understanding, support affected individuals and families, and drive continued research toward improved diagnosis and care. Join us in recognizing Fragile X Awareness Day by sharing this post and helping raise awareness. Every conversation brings us one step closer to greater understanding and progress. #FragileXAwareness #Genomics #GenomicResearch

We're excited to announce that Nabsys has signed a lease for a new 30,000-square-foot headquarters in Providence's 195 District, marking an important milestone as we continue to grow and expand commercialization of our OhmX™ Platform. Opening in 2027, our new headquarters will bring manufacturing, technology development, R&D, and business operations together under one roof - creating a collaborative space designed to support the next phase of innovation in electronic genome mapping. We're grateful for the continued support of Governor Dan McKee, the Rhode Island Commerce Corporation, the Rhode Island Life Science Hub, and the I-195 Redevelopment District Commission as we invest in the future of genomics and Rhode Island's thriving life sciences ecosystem. 👉 Read the full announcement: hubs.ly/Q04pwksq0 #LifeSciences #Innovation #RhodeIsland #GenomeMapping

Meet another one of our #OurNabsterHeroes, Jennet - using her voice to make a difference beyond the workplace. Outside of her work at Nabsys, she volunteers with Love Life Now Foundation (LLN), a nonprofit dedicated to domestic violence awareness, prevention, and survivor support. Through her volunteer work, she creates social media content that raises awareness, highlights survivor resources, and shares the impact of initiatives like the Get Safe Fund, Pajama Drive, and White Ribbon Night Gala. For Jennet, the connection between her volunteer work and her role at Nabsys comes down to a shared purpose: "Although the work looks different on the surface, both roles come down to helping people. At Nabsys, I use precision, collaboration, and problem-solving to support technology that can ultimately improve health outcomes. At LLN, those same qualities help raise awareness and support survivors of domestic violence. Different fields, but the same motivation - using my skills to make a real difference in people's lives." We're proud to have her on the team where she makes an impact both in and outside the workplace! #NabsterHero

We're proud to announce Alka Chaubey, Ph.D., FACMG as our first Chief Medical and Genomics Officer! A recognized leader in cytogenomics and structural variant analysis, Dr. Chaubey brings more than 20 years of experience advancing genome mapping technologies and driving their adoption across genomics and clinical research applications. Her appointment marks an exciting milestone as Nabsys continues to expand commercialization of the OhmX™ Platform and advance the adoption of Electronic Genome Mapping (EGM) across cancer, constitutional genetics, and cell and gene therapy research. We look forward to the leadership, expertise, and strategic perspective Alka will bring as we accelerate our next phase of growth. Read the full announcement: hubs.ly/Q04nrrJW0 #Leadership #StructuralVariants #PrecisionMedicine #LifeSciences

🏆 We're proud to share that Nabsys has been recognized as a Diamond Recipient in the 2026 Pinnacle Technology Awards for Precision Medicine Innovation! This recognition reflects our team's commitment to advancing genomic technologies that enable deeper insights into genomic structural variation and support the future of precision medicine. A huge thank you to our talented employees, collaborators, customers, and partners who make this work possible. We're honored to be recognized alongside so many innovators driving meaningful advances in technology. 👉 Learn more: hubs.ly/Q04npfPX0 #PrecisionMedicine #Genomics #Innovation #EGM #PinnacleAwards

Is your genomic integrity workflow ready for the future of cell and gene therapy? As CGT development advances, so do the expectations for comprehensive genomic characterization. Traditional methods each have strengths, but they can leave critical gaps in detecting structural variants. In our latest blog, we explore how evolving regulatory guidance and technologies like electronic genome mapping (EGM) are helping researchers build greater confidence in genomic integrity throughout the development process. 👉 Read the full blog: hubs.ly/Q04n9QzT0 #CellTherapy #GeneTherapy #PrecisionMedicine #LifeSciences

Looking to make an impact in genomics and cytogenomics? Join the team at Nabsys and help advance innovation that empowers science for all! 🧬 🔗 Check out our job openings here: - Scientist, SDO Laboratory: hubs.ly/Q04mCT0M0 - Application Scientist: hubs.ly/Q04mFX_80 - Technical Support Scientist: hubs.ly/Q04mCVtw0 - Senior Software Engineer: hubs.ly/Q04mCRqF0 - Quality Assurance Scientist: hubs.ly/Q04mFDS-0 - Principal Mechanical Engineer: hubs.ly/Q04mFNs60 #WeAreHiring

Last week, members of the Nabsys team attended the 2026 Best Places to Work in Rhode Island awards ceremony hosted by Providence Business News to celebrate this incredible recognition. 🎉 Being named one of Rhode Island's Best Places to Work is a reflection of the talented, collaborative, and passionate people who make Nabsys what it is. We're grateful to our team for fostering a culture of innovation, support, and shared purpose every day. Congratulations to all of this year's honorees - we're proud to be among such an outstanding group of organizations! #NabsterHeroes #PBNBPTW #BestPlacesToWork #RhodeIsland #LifeSciences

Thank you, #ESHG2026! We had a fantastic week connecting with researchers, collaborators, and the global human genetics community. Thank you to everyone who stopped by our booth, attended our poster presentation, and shared thoughtful conversations about the future of genomic research. 🧬 We look forward to continuing these conversations and seeing you at future meetings! #ESHG #Genomics #EGM #StructuralVariants #RareDisease

We're proud to announce a collaboration with the Leiden University Medical Center (LUMC), a global leader in FSHD research and diagnostics, to evaluate an electronic genome mapping (EGM) based assay on the OhmX™ Platform for genomic analysis of facioscapulohumeral muscular dystrophy (FSHD). “We are excited to be working with Nabsys to investigate the use of EGM to advance FSHD research,” said Prof. dr. ir. Silvère van der Maarel, Professor of Medical Genetics and Department Chair, Human Genetics at the Leiden University Medical Center. We also presented new data demonstrating how the OhmX Platform, combined with CRISPR/Cas9 optimization, can improve detection and sizing of challenging repeat expansions, including those associated with Fragile X syndrome and Friedreich's ataxia. Together, these advancements highlight the growing potential of EGM to address complex genomic regions that remain difficult to analyze with traditional methods. 👉 Read the full press release here: hubs.ly/Q04ljhqD0 #EGM #RareDisease #FSHD #FragileX #FriedreichsAtaxia

We’re excited to present our poster at #ESHG2026! 🧬 Join the Nabsys team as we share how Electronic Genome Mapping (EGM) can be paired with CRISPR/Cas9 customization to enable targeted repeat expansion analysis. 📍 Poster http://P23.023.E: CRISPR/Cas9 customization of repeat expansion assays detected via electronic genome mapping by John F. Thompson, PhD, Principal Application Scientist at Nabsys 📅 Monday, June 15, 2026 | 12:45 - 1:45 PM CEST Stop by to learn more about our latest findings and connect with the team during the session. #ESHG2026 #HumanGenetics #Genomics #StructuralVariants #Cytogenomics

We’re excited to sponsor #ESHG2026 for the very first time! What to expect at ESHG: 📍 A poster presentation highlighting repeat expansion detection with EGM 💡 Discussions on the future of structural variant analysis 🤝 Opportunities to connect with our team at the booth all week long Throughout the conference, Nabsys will be sharing how Electronic Genome Mapping (EGM) is enabling structural variant detection and supporting next-generation genomic research. If you’re attending ESHG, stop by and say hello. We’d love to connect! 👉 Schedule a meeting: hubs.ly/Q04j-0jZ0 #ESHG #HumanGenetics #EGM #GenomicsResearch

We were pleased to have Nabsys featured in Providence Business First in an article highlighting the recent installment of multiple OhmX™ Platforms in the lab of cytogeneticist Dr. Brynn Levy at Columbia University Vagelos College of Physicians and Surgeons! The installations are a part of our Rapid Application to Market Penetration User Partnership (RAMP UP) program in partnership with @Hitachi_HTA to support research using electronic genome mapping (EGM) in leading labs. Using the OhmX Platform, Dr. Levy aims to advance applications of EGM in hematological malignancies, starting with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). See the full article to learn more! hubs.ly/Q04jY9DW0 #hememalignancies #genomemapping #press

Friedreich's Ataxia is caused by GAA repeat expansions in the FXN gene. These long repetitive sequences can be difficult to fully characterize with sequencing-based approaches, particularly when both alleles carry large expansions. While repeat-primed PCR (RP-PCR) is commonly used to identify FXN expansions, Nabsys' Electronic Genome Mapping (EGM) directly sizes both alleles from individual DNA molecules, providing quantitative repeat measurements and insight into repeat-length variability. With EGM, researchers can: • Directly measure FXN GAA repeat lengths • Characterize samples with two expanded alleles • Assess repeat-length variability at the molecule level • Detect structural variants and many other repeat expansions in the same assay Learn more by downloading our FXN technical note: 👉 hubs.ly/Q04jCGKJ0 #StructuralVariation #FriedreichsAtaxia #RareDisease #AtaxiaResearch #Cytogenomics

Nothing better than seeing the sunshine finally make an appearance in Providence, RI! ☀️ As the weather warms up, we love seeing our team taking a quick break, getting outside, and spending time together beyond the usual meetings and emails. Here’s to longer days, fresh air, and a strong team heading into summer!

Thank you to everyone who connected with us at #ACC2026 in San Diego! It was an exciting week kicked off by our recent announcement regarding new OhmX™ Platform installations under Hitachi High-Tech America’s RAMP UP program in collaboration with Dr. Brynn Levy to support research in hematologic malignancies. We’re also grateful to everyone who stopped by our booth, attended our presentations and poster sessions, and participated in our “OhmX Marks the Spot” scavenger hunt throughout the meeting. From scientific discussions to networking and a little fun offsite, ACC 2026 was a fantastic opportunity to connect with colleagues and partners across the field. Thank you to the organizers for a fantastic event and we’re looking forward to continuing the conversations and collaborations sparked at ACC! #Cytogenomics #Hememalignancies #EGM

Nabsys is proud to be presenting two posters at the American Cytogenomics Conference 🧬: 📍 Electronic Genome Mapping Enables Structural Variant Analysis in Archived Methanol–Glacial Acetic Acid-Fixed Cytogenomic Cell Preparations, presented by Alden Huang, PhD, Assistant Professor at University of California, Los Angeles Pathology & Laboratory Medicine 📍 High-Resolution Detection of Blood Cancer-Specific Structural Variants Using Electronic Genome Mapping, presented by Lily Nasanovsky, PhD, Software Applications Support at Nabsys We look forward to sharing our latest work in EGM and connecting with the cyto and molecular genetics community. #ACC2026 #Cytogenomics #Hememalignancies #EGM

Join our presentations at @ACC_Genomics 2026 🎤 🔉 Resolving Structural Variants Relevant to Hematologic Malignancies using Nabsys Electronic Genome Mapping presented by Edd Lee, Global Vice President, Sales and Marketing at Nabsys 📅 Monday, May 18, 2026 ⏰ 12:30–1:00 PM PST 🔉 CRISPR-Assisted Electronic Genome Mapping for Robertsonian Translocations presented by John F. Thompson, Principal Application Scientist at Nabsys 📅 Wednesday, May 20, 2026 ⏰ 9:15-9:30 AM PST #EGM #ACC2026 #Cytogenomics

Heading to the Great Lakes Genomics Conference (GLGC) in Toronto on Friday? So are we! Be sure to stop by our table to connect with the team and learn more about high-resolution, accessible structural variant detection via electronic genome mapping (EGM). Looking forward to seeing familiar faces and making new connections in the genomics community! 🧬 👉 Book a meeting with us: hubs.ly/Q04gxxnc0 #GLGC2026 #EGM #genomicresearch

We’re heading to ACC 2026 in San Diego 🌴⚡️ Join Nabsys throughout the week as we showcase how Electronic Genome Mapping (EGM) is expanding what’s possible in cytogenomics. Here’s what we have planned: 🧬 Two talks featuring the latest advancements in EGM 🍻 Monday night: EGM Innovators Unwind - an evening to connect with fellow innovators outside of sessions 🔍 OhmX Marks the Spot - our ACC scavenger hunt, where you can find clues in exchange for prizes Stop by our booth to meet the team and learn more. 👉 Book a meeting with us: hubs.ly/Q04gnH8N0 #ACC2026 #Cytogenomics #EGM #OhmXMarksTheSpot